Tecvayli (teclistamab)
Multiple Myeloma
ApprovedCommercial
Key Facts
About Genmab
Genmab is a leading biotechnology company focused on creating and developing differentiated antibody therapeutics for the treatment of cancer. Founded in 1999 and headquartered in Copenhagen, Denmark, the company has established itself as a pioneer in antibody engineering with proprietary technology platforms including DuoBody and HexaBody. Genmab has multiple approved products generating significant revenue and maintains strategic partnerships with major pharmaceutical companies including Janssen, AbbVie, and Roche.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Darzalex (daratumumab) | Johnson & Johnson | Approved |
| JNJ-4528 (CAR-T) | Johnson & Johnson | Phase 3 |
| Elrexfio | Pfizer | Approved |
| Revlimid (lenalidomide) | Bristol Myers Squibb | Commercial |
| Abecma (idecabtagene) | Bristol Myers Squibb | Commercial |
| Blenrep (belantamab mafodotin) | GSK plc | Approved |
| ABBV-383 | AbbVie | Phase 1/2 |
| REGN5458 | Regeneron Pharmaceuticals | Phase 1/2 |
| Ninlaro (ixazomib) | Takeda Pharmaceutical | Commercial |
| Talquetamab | Genmab | Phase 3 |
| Lenalidomide (Generic Revlimid) | Dr. Reddy's Laboratories | Approved |
| YH29407 | Yuhan | Phase 1 |